**HETEROCYCLES, Vol.53, No. 9, 2000, pp. 1885 - 1889, Received, 26th June, 2000** 

## **TOWARDS THE SYNTHESIS OF SCYPHOSTATIN**

Mukund K Gurjar\* and Srinivas Hotha

Division of Organic Chemistry: Technology National Chemical Laboratory, Pune-411 008, India

**Abstract -** Stereocontrolled synthesis of the substituted cyclohexenone segment (**2**) of scyph-ostatin (**1**) is described starting from D-glucose.

Scyphostatin  $(1)$  is a novel neutral sphingomyelinase (N-Smase) inhibitor isolated<sup>1</sup> during the search for N-Smase inhibitors from the fermentation broth of *Dascysphus mollissimus* SANK-13892. N-Smase inhibitors are useful in the regulation of ceramide level and thus are of immense need in the therapy of autoimmune diseases and inflammation.<sup>2</sup> Scyphostatin (1) is a structurally unique natural product containing an unprecedented cyclohexenone epoxide moiety in which the *tertiary* chiral center at C-4 is linked to an *n*-propylamino alcohol and a lipophilic side chain[C(1´)-C(20´)]. The structure of scyphostatin (**1**) was determined by NMR and MS spectral studies. Chemical and spectroscopic analysis, coupled with modified Mosher's method, provided stereo-



chemical configuration of the cyclohexenone epoxide ring structure of scyphostatin. However, the initial report did not confirm the absolute configuration of the lipophilic side chain. Later Saito *et al.* has confirmed<sup>3</sup> the absolute and relative configurations by degradation of **1** and chemical correlation to synthetic fragments. Hoye *et al.*<sup>4</sup> have synthesized the lipophilic side chain and till date there is no single report on synthesis of polar cyclohexenone moiety. As part of our interest, we have embarked on developing a carbohydrate based strategy to prepare the suitably substituted cyclohexenone derivative (**2**) present in the scyphostatin (**1**). D-Glucose was converted5 into methyl 3-*O*-benzyl-4,6-benzylidene-α-D-glucopyranoside (**3**) whose oxidation at C-2 under

Swern conditions, gave the 2-ulose derivative (4) (Scheme 1).<sup>6</sup> Subsequent *C*-allylation of 4 was studied<sup>7</sup> under various conditions. However, we observed that 4 with allylmagnesium bromide in anhydrous ether/CH<sub>2</sub>Cl<sub>2</sub> at – 78 <sup>o</sup> C gave a 9:1 diastereomeric mixture of *tertiary* alcohols (**5a**) and (**5b**) which were separated by silica gel column chromatography. The major product was subjected to NOE studies which unequivocally proved the structure as **5a** while the structure of the minor product (**5b**) was unambiguously assigned based on interesting chemical transformations.7b



Scheme 1: a) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, -78 <sup>o</sup>C, 89 %; b) allylmagnesium bromide, Et<sub>2</sub>O:CH<sub>2</sub>Cl<sub>2</sub> **(4:1), -78 °C, 68 %; c) NaH, BnBr, DMF, n-Bu<sub>4</sub>NI, , 0 °C-rt, 97 %.** 

The derived O-benzyl derivative  $(6)$  was reduced<sup>8</sup> with LiAlH<sub>4</sub>-AlCl<sub>3</sub> to give rise to the 4-O-benzyl derivative (7) containing a primary hydroxy group at C-6. Treatment of 7 with  $Ph_3P-I_2$ -imidazole in toluene gave<sup>9</sup> the 6deoxy-6-iodo derivative (**8**) (Scheme **2**). Catalytic osmylation of **8** in *t*-butanol-water gave a 4:1 mixture of diastereomeric products whose acetonide derivatives (**9a/9b)** could be separated by silica gel column chromatography. In accordance with Sharpless modifications,<sup>10</sup> use of AD-MIX- $\alpha$  provided predominantly the diastereomer (**9b**) whose stereochemical assignments were based on hypothesis reported by Sharpless *et al* .<sup>10</sup> Compound (9b) was treated with DBU in DMF at  $100^{\circ}$ C for 12 h to give the 5,6-ene derivative (10). The Ferrier rearrangement<sup>11</sup> of 10 in the presence of  $Hg(OAc)$  in aqueous acetone gave the carbocyclic derivative (**11**) whose dehydration in the presence of MsCl-Et<sub>3</sub>N-CH<sub>2</sub>Cl<sub>2</sub> provided the  $\alpha$ , β-unsaturated derivative (**12**) (Scheme 3). In order to rearrange **12**, into the target structure (**2**), an approach based on Barton's radical opening reaction<sup>12</sup> of  $\alpha$ , β-epoxythioimidazolide was investigated (Scheme 3).

Compound (12) was epoxidised with 30 % hydrogen peroxide-K<sub>2</sub>CO<sub>3</sub> in THF-H<sub>2</sub>O to give 13 which was consequently reduced with  $N$ aBH<sub>4</sub> in methanol to give the epoxy alcohol (14). In the <sup>I</sup>H-NMR spectrum of **14,** epoxy protons were clearly visible at 3.23 (doublet,  $J = 3.8$  Hz) and 3.35 ppm (triplet,  $J = 3.8$  Hz). Conversion of **14** into the thiocarbonate derivative (**15**) was accomplished with *N,N'*-thiocarbonyldiimidazole in

refluxing  $C_6H_6$ . The <sup>1</sup>H-NMR spectrum of **15** showed characteristic downfield shift of the proton carrying



Scheme 2: a) LiAlH<sub>4</sub>, AlCl<sub>3</sub>, Et<sub>2</sub>O, 15 min, 90 %; b) PPh<sub>3</sub>, Im, I<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>Me, reflux, 2 h, 95 %; c) AD-mix**α**, *t***-BuOH-H<sub>2</sub>O (1:1), 0 °C, 24 h, 89 %; d) DMP, PTSA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 30 min, 98 %; e) DBU, DMF, 100 °C, 12 h, 48 %; f) Hg(OAc)2, MeCOMe, H2O (3:1), reflux, 5 h, 80 %;g) MsCl, Et3N, CH2Cl2, rt, 3 h, 85 %** 

thiocarbonate group. Treatment of **15** with Bu3SnH and cat. AIBN in refluxing benzene gave a mixture of products from which the major product was isolated (30 %) by silica gel chromatography. Subsequent oxidation with  $MnO_2$  in refluxing  $CH_2Cl_2$  provided the target cyclohexenone derivative (2). In the <sup>1</sup>H-NMR spectrum of **2**, the characteristic<sup>13</sup> signals due to olefinic protons were located at 5.96 (dd,  $J = 2.04$ , 10.39 Hz) and 6.85 ppm (dd,  $J = 1.89$ , 10.39 Hz). Rest of the spectral data was in conformity with the assigned structure (2).<sup>14</sup>



Scheme 3: a)  $H_2O_2$ , K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, THF, 0<sup>o</sup>C, 6 h, 65 %; b) NaBH<sub>4</sub>, MeOH, -40<sup>o</sup>C, 15 min, 93 %; c) Im- $C(=S)$ Im,  $C_6H_6$ , 80<sup>°</sup>C, 12 h, 98 %; d) Bu<sub>3</sub>SnH, AIBN,  $C_6H_6$ , 80<sup>°</sup>C, 4 h, 30 %; e) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 45<sup>°</sup>C, **87%.**

In conclusion we have reported for the first time the stereocontrolled synthesis of a novel and highly substituted cyclohexenone ring system of scyphostatin.

## **ACKNOWLEDGEMENT**

SH thanks CSIR, New Delhi for the financial support in the form of Senior Research Fellowship.

## **REFERENCES**

- 1. M. Tanaka, F. Nara, K-K. Suzuki, T. Hosoya, and T. Ogita, *J. Am. Chem. Soc.,* 1997, **119**, 7871.
- 2. L. M. Obeid, and Y. A. Hannun, *J. Cell. Biochem.,* 1995, **58**, 191; b) Y. A. Hannun, *Science,* 1996, **274**, 1855; c) S. Spiegel, and A. Merrill *FASEB. J*., 1996, **10**, 1388; d) R. Kolesnick, and D. W. Golde, *Cell,* 1994, **77**, 325; e) L. R. Ballou, S. J. F. Laulederkind, E. F. Rosloniec, and R. Raghow, *Biochim. Biophys. Acta,* 1996, **1301**, 273.
- 3. S. Saito, N. Tanaka, K. Fujimoto, and H. Kogen, *Org. Lett.*, 2000, **2**, 505.
- 4. T. R. Hoye, and M. A. Tennakoon, *Org. Lett.*, 2000, **2**, 1481.
- 5. E. J. Roberts, C. P. Wade, and S. P. Rowland, *Carbohydr. Res.*, 1972, **21**, 357.
- 6. M. E. Jung, and S. W. T. Choe, *J. Org. Chem.*, 1995, **60**, 3280.
- 7. a) D. J. Holt, W. D. Barker, P. R. Jenkins, D. L. Davies, S. Garratt, J. Fawcett, D. R. Russell, and S. Ghosh, *Angew. Chem., Int. Engl. Ed.*, 1998**, 37**, 3298; b) The following chemical transformations were carried out in order to prove the structural integrity of compound (**5b)** unequivocally.



**a) NaH, BnBr, DMF, rt, 90%; b) LiAlH4, AlCl3, Et2O, CH2Cl2, 15 min, 95%; c) (i) (COCl)2, DMSO,**  Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, -78<sup>o</sup>C, 80%; (ii) Ph<sub>3</sub>P=CH<sub>2,</sub> THF, 65%; d) Grubbs catalyst, C<sub>6</sub>H<sub>5</sub>Me, reflux, 3 days, **45%.** 

- 8. S. G. Zeller, G. W. Griesgrabu, and G. R. Gray, *Carbohydr. Res.*, 1991, **211**, 47; S. S. Bhattacharya, and P. A. J. Gorin, *Can. J. Chem.*, 1969, **47**, 1195.
- 9. P. J. Garegg, and B. Samuelsson, *J. Chem. Soc. Perkin Trans. 1*, 1980, 2866.
- 10. K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K-S. Jeong, H-L. Kwong, K. Morikarwa, Z-M. Wang, D. Xu, and X-L. Zhang, *J. Org. Chem.*, 1992, **57**, 2768.
- 11. R. J. Ferrier, and S. Middleton, *Chem. Rev*., 1993, **93**, 2779; b) R. Blattner, R. J. Ferrier, and S. R. Haines,  *J. Chem. Soc., Perkin Trans. 1*, 1985, 2413.
- 12. D. H. R. Barton, R. S. H. Motherwell, and W. B. Motherwell, *J. Chem. Soc., Perkins Trans. 1*, 1981, 2363.
- 13. a) K. Sato, M. Bokura, and M. Taniguchi, *Bull. Chem. Soc. Jpn.*, 1994, **67**, 1633; b) W. Zhao, G. Qin, R-Z.

Yang, T-Y. Jiang, W-X. Li, L. Scott, and J. K. Snyder, *Tetrahedron*, 1996, **52**, 12373; c) R. Hollands, D. Becher, and G. Polonsky, *Tetrahedron*, 1968, **24**, 1633.

14. Structures of new compounds were established by <sup>1</sup>H NMR, FABMS/HRMS or microanalysis. The <sup>1</sup>H NMR spectral data of some key intermediates are given below:

**5a**  $(400 \text{ MHz}, \text{CDCl}_3)$ : 2.29  $(\text{dd}, 1 \text{ H}, \text{J} = 7.6, 15.3 \text{ Hz})$ , 2.57  $(\text{dd}, 1 \text{ H}, \text{J} = 3.8, 15.3 \text{ Hz})$ , 3.35  $(s, 3 \text{ H})$ , 3.65 (d, 1 H, J = 7.7 Hz), 3.83 (m, 2 H), 4.10 (m, 1 H), 4.32 (m, 1 H), 4.40 (s, 1 H), 4.65, 4.95 (ABq, 2 H, J = 15.6 Hz), 5.10 (m, 2 H), 5.60 (s, 1 H), 5.85 (m, 1 H), 7.30 (m, 10 H); **8** (200 MHz, CDCl3): 2.27 (dd, 1 H, J  $= 9.0, 14.5 \text{ Hz}$ ), 3.09 (dd, 1 H, J = 4.5, 14.5 Hz), 3.27 (dd, 1 H, J = 6.8, 10.0 Hz), 3.38 (s, 3 H), 3.45 (m, 2 H), 3.75 (d, 2 H, J = 4.5 Hz), 4.52, 4.73 (ABq, 2 H, J = 10.2 Hz), 4.61, 4.79 (ABq, 2 H, J = 11.4 Hz), 4.65, 4.88 (ABq, 2 H, J = 10.9 Hz), 4.72 (s, 1 H), 5.11 (m, 2 H), 5.81 (m, 1 H), 7.30 (m, 15 H); **9** (200 MHz, CDCl<sub>3</sub>): 1.29, 1.36 (2s, 6 H), 1.70 (dd, 1 H, J = 9.0, 15.9 Hz), 2.77 (dd, 1 H, J = 4.3, 15.9 Hz), 3.29 (dd, 1 H, J = 8.1, 11.3 Hz), 3.40 (s, 3 H), 3.47 (t, 3 H, J = 9.0 Hz), 3.75 (m, 2 H), 3.95 (dd, 1 H, J = 6.8 Hz), 4.20  $(m, 1 H)$ , 4.45 (s, 1 H), 4.63, 4.79 (ABq, 2 H, J = 11.5 Hz), 4.70, 4.90 (ABq, 2 H, J = 11.2 Hz), 4.75, 5.06 (ABq, 2 H, J = 11.5Hz), 7.30 (m, 15 H); **12** (200 MHz, CDCl3): 1.15, 1.31 (2s, 6 H), 2.04 (m, 1H), 2.18 (dd, 1 H, J = 2.3, 15.9 Hz), 3.25 (m, 1 H), 3.56 (m, 2 H), 3.88 (d, 1 H, J = 9.0 Hz), 4.54, 4.77 (ABq, 2 H, J = 10.5 Hz), 4.61, 5.00 (ABq, 2 H, J = 11.4 Hz), 4.67, 5.11 (ABq, 2 H, J = 11.4 Hz), 4.68 (d, 1 H, J = 9.0 Hz), 6.04 (d, 1 H, J = 9.0 Hz), 6.90 (d, 1 H, J = 9.0 Hz), 7.30 (m, 15 H); **2** (500 MHz, CDCl<sub>3</sub>): 1.22, 1.30 (2s, 6) H), 2.05 (dd, 1 H, J = 5.0, 13.8 Hz), 2.69 (dd, 1 H, J = 7.5, 13.7 Hz), 3.53 (t, 1 H, J = 7.7 Hz), 3.98 (d, 1 H, J  $= 7.4$  Hz), 4.00 (t, 1 H, J = 7.6 Hz), 4.14 (m, 1 H), 4.42, 4.60 (ABq, 2 H, J = 11.6 Hz), 4.78 (s, 2 H), 4.75, 5.13 (ABq, 2 H, J = 11.6 Hz), 4.77 (ddd, 1 H, J = 1.9, 2.1, 7.7 Hz), 5.96 (dd, 1 H, J = 2.1, 10.4 Hz), 6.85 (dd, 1H,  $J = 1.89$ , 10.4 Hz), 7.3 (m, 15 H).